Drug Type Biosimilar, Monoclonal antibody |
Synonyms Bevacizumab Biosimilar (United BioPharma, Inc.), UB-922 |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Brain Cancer | Preclinical | China | 01 Jan 2018 | |
Colorectal Cancer | Preclinical | China | 01 Jan 2018 | |
Non-Small Cell Lung Cancer | Preclinical | China | 01 Jan 2018 | |
Renal Cell Carcinoma | Preclinical | China | 01 Jan 2018 |